UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |---------------------------------------------------------------------------------------------------------|------------------------------------------| | For the transition ...

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates ADI-001 Phase 1 clinical trial expanded to include a total of six autoimmune disease indications; preliminary clinical data in lupus nephritis (LN) anticipated in 1H25 Strong balance sheet with $202.1 million in cash, cash equivalents and short-term investments as of September 30, 2024 REDWOOD CITY, Calif. & BOSTON – November 6, 2024 – Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and deve ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adicet Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 81-3305277 (State or other jurisdiction o ...

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates ADI-001 autoimmune clinical development expanded beyond lupus nephritis (LN) to include systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV), following recent U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearances IND clearance for ADI-270 for the treatment of patients with relapsed/refractory renal cell carcinom ...

Adicet Bio (ACET) gained 9.4% on Jul 8 and continued to gain another 2.6% during the after-market hours after the FDA granted Fast Track designation to its investigational candidate, ADI-270, for the potential treatment of patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC). ccRCC is a form of kidney cancer.The eligible patient population for the candidate includes ccRCC patients who have been treated with an immune checkpoint inhibitor and a vascular endothelial growth factor inhibito ...

One of the ways to make millions from the market is to identify and invest in early-stage companies. If the business takes off, multi-fold returns are in the offering. Of course, the risk involved is high and investors should limit portfolio exposure to these companies at 5% to 10%.One sector that’s worth researching for early-stage ideas is biotech. There are dozens of listed clinical-stage biotech stocks. If clinical trials deliver positive results and the product is commercialized, the revenue upside pot ...

Biotech stocks are always interesting from a trading perspective. With dozens of companies in the clinicalstage, positive news from trials can be a big catalyst for a scintillating rally. Biotech stocks were however subdued in a post-pandemic world with focus shifting to other sectors. This has translated into undervalued in several interesting biotech stocks under $10. An important point to note is that clinical-stage biotech stocks are participants in a meme stock rally. With multiple rate cuts likely in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adicet Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 81-3305277 (State or other jurisdiction ...

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates On track to initiate Phase 1 clinical trial evaluating ADI-001 in lupus nephritis in 2Q 2024 Presented promising preclinical data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting; on track to file investigational new drug (IND) in renal cell carcinoma in 2Q 2024 Strong balance sheet with $247.6 million in cash and cash equivalents as of March 31, 2024 REDWOOD CITY, Calif. & BOSTON – May 14, 20 ...

One stock that might be an intriguing choice for investors right now is Adicet Bio, Inc. (ACET) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place ...